WGU D116 ADVANCED PHARMACOLOGY FINAL EXAM
2026/2027 Academic Year
80 Questions and Correct Answers
Already Graded A+ | 100% Verified
Core Domains:
Advanced Pharmacokinetics & Pharmacodynamics | Drug Classifications & Mechanisms
Medication Safety & ADRs | Cardiovascular & Endocrine Pharmacology
Neurological & Psychiatric Medications | Anti-Infectives | Pain Management
Drug Interactions | Patient Education | Evidence-Based Decision-Making
WGU Program–Aligned Format
, WGU D116 Advanced Pharmacology Final Exam 2026/2027
Table of Contents
Table of Contents .......................................................................................................................................... 2
Introduction .................................................................................................................................................. 3
Domain 1: Advanced Pharmacokinetics & Pharmacodynamics ................................................................ 4
Domain 2: Drug Classifications & Mechanisms of Action ......................................................................... 6
Domain 3: Medication Safety & Adverse Drug Reactions .......................................................................... 9
Domain 4: Cardiovascular & Endocrine Pharmacology ............................................................................ 11
Domain 5: Neurological & Psychiatric Medications .................................................................................. 14
Domain 6: Anti-Infectives ........................................................................................................................... 17
Domain 7: Pain Management & Analgesics ............................................................................................... 19
Domain 8: Drug Interactions ..................................................................................................................... 22
Domain 9: Patient Education..................................................................................................................... 25
Domain 10: Evidence-Based Pharmacologic Decision-Making ................................................................27
Answer Key .................................................................................................................................................. 31
Note: This Table of Contents is generated via field codes. To ensure page number accuracy after
editing, please right-click the TOC and select "Update Field."
Page 2 of 31
, WGU D116 Advanced Pharmacology Final Exam 2026/2027
Introduction
The WGU D116 Advanced Pharmacology Final Exam for the 2026/2027 academic cycle is a
comprehensive assessment designed to evaluate advanced pharmacologic knowledge in healthcare
programs. This examination measures proficiency in medication mechanisms of action, therapeutic
uses, adverse reactions, drug interactions, and safe evidence-based pharmacologic decision-making in
patient care.
This examination consists of 80 multiple-choice questions in single-best-answer format, including
scenario-based pharmacology and clinical decision-making items. Each question includes a detailed
rationale explaining pharmacologic principles, medication safety considerations, and evidence-based
clinical reasoning. All correct answers are presented in bold and green format for easy
identification.
Page 3 of 31
, WGU D116 Advanced Pharmacology Final Exam 2026/2027
Domain 1: Advanced Pharmacokinetics & Pharmacodynamics
1. A patient with renal impairment has a creatinine clearance of 25 mL/min. Which pharmacokinetic
parameter will be most significantly affected?
A. Elimination half-life
B. Absorption rate
C. Protein binding
D. Distribution volume
Rationale: Renal impairment significantly affects drug elimination, resulting in prolonged half-life
for drugs that are primarily excreted renally. This requires dose adjustment to prevent drug
accumulation and toxicity. While protein binding and distribution may be affected by uremia, and
absorption can be altered, elimination is most directly impacted by reduced renal function.
2. A drug follows first-order kinetics. Which statement accurately describes this pharmacokinetic
model?
A. A constant fraction of drug is eliminated per unit time
B. A constant amount of drug is eliminated per unit time
C. The elimination rate is independent of drug concentration
D. Half-life increases as drug concentration increases
Rationale: In first-order kinetics, a constant fraction (percentage) of drug is eliminated per unit
time, regardless of the drug concentration. The elimination rate is directly proportional to
concentration. This results in a constant half-life. In zero-order kinetics, a constant amount is
eliminated per time. Most drugs follow first-order kinetics within therapeutic ranges.
3. A patient is taking a drug that is 95% protein-bound. If another highly protein-bound drug is
added, what is the most likely clinical consequence?
A. Increased free drug concentration of the first drug, potentially causing toxicity
B. Decreased free drug concentration of the first drug
C. No change in free drug concentration
D. Increased protein synthesis
Rationale: When two highly protein-bound drugs compete for binding sites, one drug can displace
the other, increasing the free (active) concentration of the displaced drug. This can lead to enhanced
effects or toxicity. The clinical significance depends on the drugs' therapeutic indices. This is
particularly important for drugs like warfarin, phenytoin, and certain NSAIDs.
4. A drug has a volume of distribution (Vd) of 200 L in a 70-kg patient. What does this indicate about
the drug's distribution?
Page 4 of 31
2026/2027 Academic Year
80 Questions and Correct Answers
Already Graded A+ | 100% Verified
Core Domains:
Advanced Pharmacokinetics & Pharmacodynamics | Drug Classifications & Mechanisms
Medication Safety & ADRs | Cardiovascular & Endocrine Pharmacology
Neurological & Psychiatric Medications | Anti-Infectives | Pain Management
Drug Interactions | Patient Education | Evidence-Based Decision-Making
WGU Program–Aligned Format
, WGU D116 Advanced Pharmacology Final Exam 2026/2027
Table of Contents
Table of Contents .......................................................................................................................................... 2
Introduction .................................................................................................................................................. 3
Domain 1: Advanced Pharmacokinetics & Pharmacodynamics ................................................................ 4
Domain 2: Drug Classifications & Mechanisms of Action ......................................................................... 6
Domain 3: Medication Safety & Adverse Drug Reactions .......................................................................... 9
Domain 4: Cardiovascular & Endocrine Pharmacology ............................................................................ 11
Domain 5: Neurological & Psychiatric Medications .................................................................................. 14
Domain 6: Anti-Infectives ........................................................................................................................... 17
Domain 7: Pain Management & Analgesics ............................................................................................... 19
Domain 8: Drug Interactions ..................................................................................................................... 22
Domain 9: Patient Education..................................................................................................................... 25
Domain 10: Evidence-Based Pharmacologic Decision-Making ................................................................27
Answer Key .................................................................................................................................................. 31
Note: This Table of Contents is generated via field codes. To ensure page number accuracy after
editing, please right-click the TOC and select "Update Field."
Page 2 of 31
, WGU D116 Advanced Pharmacology Final Exam 2026/2027
Introduction
The WGU D116 Advanced Pharmacology Final Exam for the 2026/2027 academic cycle is a
comprehensive assessment designed to evaluate advanced pharmacologic knowledge in healthcare
programs. This examination measures proficiency in medication mechanisms of action, therapeutic
uses, adverse reactions, drug interactions, and safe evidence-based pharmacologic decision-making in
patient care.
This examination consists of 80 multiple-choice questions in single-best-answer format, including
scenario-based pharmacology and clinical decision-making items. Each question includes a detailed
rationale explaining pharmacologic principles, medication safety considerations, and evidence-based
clinical reasoning. All correct answers are presented in bold and green format for easy
identification.
Page 3 of 31
, WGU D116 Advanced Pharmacology Final Exam 2026/2027
Domain 1: Advanced Pharmacokinetics & Pharmacodynamics
1. A patient with renal impairment has a creatinine clearance of 25 mL/min. Which pharmacokinetic
parameter will be most significantly affected?
A. Elimination half-life
B. Absorption rate
C. Protein binding
D. Distribution volume
Rationale: Renal impairment significantly affects drug elimination, resulting in prolonged half-life
for drugs that are primarily excreted renally. This requires dose adjustment to prevent drug
accumulation and toxicity. While protein binding and distribution may be affected by uremia, and
absorption can be altered, elimination is most directly impacted by reduced renal function.
2. A drug follows first-order kinetics. Which statement accurately describes this pharmacokinetic
model?
A. A constant fraction of drug is eliminated per unit time
B. A constant amount of drug is eliminated per unit time
C. The elimination rate is independent of drug concentration
D. Half-life increases as drug concentration increases
Rationale: In first-order kinetics, a constant fraction (percentage) of drug is eliminated per unit
time, regardless of the drug concentration. The elimination rate is directly proportional to
concentration. This results in a constant half-life. In zero-order kinetics, a constant amount is
eliminated per time. Most drugs follow first-order kinetics within therapeutic ranges.
3. A patient is taking a drug that is 95% protein-bound. If another highly protein-bound drug is
added, what is the most likely clinical consequence?
A. Increased free drug concentration of the first drug, potentially causing toxicity
B. Decreased free drug concentration of the first drug
C. No change in free drug concentration
D. Increased protein synthesis
Rationale: When two highly protein-bound drugs compete for binding sites, one drug can displace
the other, increasing the free (active) concentration of the displaced drug. This can lead to enhanced
effects or toxicity. The clinical significance depends on the drugs' therapeutic indices. This is
particularly important for drugs like warfarin, phenytoin, and certain NSAIDs.
4. A drug has a volume of distribution (Vd) of 200 L in a 70-kg patient. What does this indicate about
the drug's distribution?
Page 4 of 31
